Phase 3 HALO data on fremanezumab in episodic migraine published in JAMA
Phase 3 HALO data demonstrating the efficacy of fremanezumab in patients with episodic migraine have been published in the Journal of the American Medical Association (JAMA). Compared to placebo, monthly fremanezumab reduced mean monthly migraine days by 1.5 days over a 12-week period, and a 1.3 day reduction was seen with single higher-dose treatment (p<0.001 for both doses). The most common adverse events that led to discontinuation were injection site erythema (n=3), injection site induration (n=2), diarrhoea (n=2), anxiety (n=2) and depression (n=2).
Read the full report here »